Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, randomized, open label study to investigate the efficacy
and safety of osimertinib plus bevacizumab versus osimertinib montherapy in treatment-naïve
recurrent or metastatic NSCLC patients harbouring EGFR exon 21 L858R mutation.